Retinal Vein Occlusion Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Kodiak Sciences, Roche/Chugai Pharmaceuticals, Novartis, Allergan

DelveInsight’s “Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Retinal Vein Occlusion, historical and forecasted epidemiology as well as the Retinal Vein Occlusion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Retinal Vein Occlusion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Retinal Vein Occlusion Market Forecast

Some of the key facts of the Retinal Vein Occlusion Market Report: 

• The Retinal Vein Occlusion market size was valued approximately USD 2,378 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• There were about 2,708,118 cases of RVO overall in the 7MM in 2021; this number is predicted to rise to 2032 at a CAGR of 1.0% for the research period (2019-2032)
• RVO was diagnosed in roughly 1,518,208 cases overall in the 7MM in 2021; this number is expected to rise by 2032 at a CAGR of 1.4% over the course of the study period (2019-2032)
• Germany had the greatest prevalence of Retinal Vein Occlusion cases among the EU-5 nations in 2021 (about 225,397 cases), with a predicted rise by 2032. In Spain, the least amount of cases were reported
• In the 7MM, there were roughly 715,167 diagnosed cases of Retinal Vein Occlusion in males and 803,041 diagnosed cases in females in the year 2021. These cases are anticipated to rise by 2032, according to the report
• RVO occurs more frequently in people who are older. For the age groups under 65, 65 to 74, and 75 years, the age-specific diagnosed prevalent cases in the 7MM were roughly 454,378, 572,552, and 491,279 cases in 2021
• TLC399 (ProDex), AR1105, GB102, ONS-5010/Lytenava, Vabysmo, and KSI-301, which is in the last phases of development, make up the dynamic pipeline for RVO. AXT107, MHU650, ANXV, autologous bone marrow CD34+ stem cells, and others are early-stage treatments in addition to these
• Key Retinal Vein Occlusion Companies: Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences, Roche/Chugai Pharmaceuticals, Novartis, Allergan, Pfizer, Aerpio Therapeutics, The Emmes Company, LLC, Regeneron Pharma, Hoffmann-La Roche, and others
• Key Retinal Vein Occlusion Therapies: TLC399, AR-1105, GB-102, ONS-5010 (Lytenava), KSI-301, Vabysmo (faricimab), ranibizumab, dexamethasone implant, AKB-9778, bevacizumab, Aflibercept, pegaptanib sodium (Macugen), TLC399 (ProDex), Faricimab, GB-102, and others
• The Retinal Vein Occlusion epidemiology based on type-specific cases analyzed that the type-specific distribution of RVO suggests a higher prevalence of BRVO than CRVO
• The Retinal Vein Occlusion market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Retinal Vein Occlusion pipeline products will significantly revolutionize the Retinal Vein Occlusion market dynamics.

Retinal Vein Occlusion Overview

After diabetic retinopathy, retinal vein occlusion (RVO) is the second most prevalent retinal vascular condition. It is characterised by thrombus formation in the central, hemi-central, or branch retinal veins. The neighbouring atherosclerotic retinal arteries’ compression is the most frequent etiological cause. External compression or diseases of the venous wall, such as vasculitis, are additional potential reasons.

Get a Free sample for the Retinal Vein Occlusion Market Report 

https://www.delveinsight.com/report-store/retinal-vein-occlusion-market

Retinal Vein Occlusion Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Retinal Vein Occlusion Epidemiology Segmentation:

The Retinal Vein Occlusion market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Retinal Vein Occlusion
• Prevalent Cases of Retinal Vein Occlusion by severity
• Gender-specific Prevalence of Retinal Vein Occlusion
• Diagnosed Cases of Episodic and Chronic Retinal Vein Occlusion

Download the report to understand which factors are driving Retinal Vein Occlusion epidemiology trends @ Retinal Vein Occlusion Epidemiology Forecast

Retinal Vein Occlusion Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Retinal Vein Occlusion market or expected to get launched during the study period. The analysis covers Retinal Vein Occlusion market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Retinal Vein Occlusion Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Retinal Vein Occlusion Therapies and Key Companies

• TLC399: Taiwan Liposome Company
• AR-1105: Aerie Pharmaceuticals
• GB-102: Graybug Vision
• ONS-5010 (Lytenava): Outlook Therapeutics
• KSI-301: Kodiak Sciences
• Vabysmo (faricimab): Roche/Chugai Pharmaceuticals
• ranibizumab: Novartis
• dexamethasone implant: Allergan
• pegaptanib sodium: Pfizer
• AKB-9778: Aerpio Therapeutics
• bevacizumab: The Emmes Company, LLC
• Aflibercept: Regeneron Pharma
• pegaptanib sodium (Macugen): Pfizer
• TLC399 (ProDex): Taiwan Liposome Company
• Faricimab: Hoffmann-La Roche
• GB-102: Graybug Vision

Discover more about therapies set to grab major Retinal Vein Occlusion market share @ Retinal Vein Occlusion Treatment Market

Retinal Vein Occlusion Market Drivers

• Rich Retinal Vein Occlusion pipeline
• Advancement in drug therapies
• Increase in knowledge and awareness
• Increasing prevalence of Retinal Vein Occlusion

Retinal Vein Occlusion Market Barriers

• Cost Consciousness
• Risk and complications
• Lack of focus on for visual restoration
• Failure of investigational drugs
• Invasion of biosimilar in future 

Scope of the Retinal Vein Occlusion Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Retinal Vein Occlusion Companies: Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences, Roche/Chugai Pharmaceuticals, Novartis, Allergan, Pfizer, Aerpio Therapeutics, The Emmes Company, LLC, Regeneron Pharma, Hoffmann-La Roche, Graybug Vision, and others
• Key Retinal Vein Occlusion Therapies: TLC399, AR-1105, GB-102, ONS-5010 (Lytenava), KSI-301, Vabysmo (faricimab), ranibizumab, dexamethasone implant, AKB-9778, bevacizumab, Aflibercept, pegaptanib sodium (Macugen), TLC399 (ProDex), Faricimab, GB-102, and others
• Retinal Vein Occlusion Therapeutic Assessment: Retinal Vein Occlusion current marketed and Retinal Vein Occlusion emerging therapies
• Retinal Vein Occlusion Market Dynamics: Retinal Vein Occlusion market drivers and Retinal Vein Occlusion market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Retinal Vein Occlusion Unmet Needs, KOL’s views, Analyst’s views, Retinal Vein Occlusion Market Access and Reimbursement 

To know more about Retinal Vein Occlusion companies working in the treatment market, visit @ Retinal Vein Occlusion Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Retinal Vein Occlusion Market Report Introduction

2. Executive Summary for Retinal Vein Occlusion

3. SWOT analysis of Retinal Vein Occlusion

4. Retinal Vein Occlusion Patient Share (%) Overview at a Glance

5. Retinal Vein Occlusion Market Overview at a Glance

6. Retinal Vein Occlusion Disease Background and Overview

7. Retinal Vein Occlusion Epidemiology and Patient Population

8. Country-Specific Patient Population of Retinal Vein Occlusion 

9. Retinal Vein Occlusion Current Treatment and Medical Practices

10. Retinal Vein Occlusion Unmet Needs

11. Retinal Vein Occlusion Emerging Therapies

12. Retinal Vein Occlusion Market Outlook

13. Country-Wise Retinal Vein Occlusion Market Analysis (2019–2032)

14. Retinal Vein Occlusion Market Access and Reimbursement of Therapies

15. Retinal Vein Occlusion Market Drivers

16. Retinal Vein Occlusion Market Barriers

17.  Retinal Vein Occlusion Appendix

18. Retinal Vein Occlusion Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services